Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
For better or worse, the Democrats incorporated a good deal of mainstream Republican thinking about health care reform from the past decade, including mandated coverage and health insurance exchanges, into the Affordable Care Act. This leaves the GOP, embarrassingly, with little to say about what is wrong with the act.
Elderly patients are at a significantly increased risk for acute myocardial infarction in the 2 weeks following total hip- or knee-replacement surgery, research shows.
Research published in the journal Age and Ageing, which studied nursing homes in the Munster region of Ireland, has found that a significant proportion of older patients have either been prescribed a potentially inappropriate medicine or they are not prescribed a medicine that would normally be beneficial.
The results of the first trial to administer the polypill on the basis of age alone has shown the largest reductions in blood pressure and cholesterol level of any polypill trial to date, researchers report.
Aspirin use appears to reduce the risk of Barrett's esophagus (BE), the largest known risk factor for esophageal cancer, according to a new study in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.
The urgent need to evaluate nature's repository of chemicals in plants, microbes, and marine organisms for their potential value in health care will be a major theme of a five-day scientific conference in New York that is expected to draw some 1,200 natural products researchers from around the world.
T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the presentation of new data on hemostasis monitoring at the American Association for Clinical Chemistry Annual Meeting, July 15-19, 2012, in Los Angeles, CA.
The interaction between proton pump inhibitors and clopidogrel is “clinically unimportant,” say researchers in the BMJ.
The platelet aggregation inhibitor ticagrelor is now considered of equal effectiveness to clopidogrel and prasugrel for patients who have experienced a heart attack or have unstable angina, a report states.
The platelet aggregation inhibitor ticagrelor is now considered of equal effectiveness to clopidogrel and prasugrel for patients who have experienced a heart attack or have unstable angina, a report states.
AstraZeneca today announced plans to conduct the EUCLID study, a global clinical trial involving 11,500 patients with peripheral artery disease (PAD), a condition affecting approximately 27 million people in Europe and North America.
Cardiology experts are supporting a call for greater attention to diagnosis and management of atrial fibrillation in primary care to prevent strokes.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
A new approach to testing medical treatment options could ensure that more patients get the most beneficial treatment for them - but still yield valuable research results that stand up to scientific scrutiny.
A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.
A patient registry is proving invaluable in cataloging the clinical features, symptoms, severity, and outcomes of fibromuscular dysplasia (FMD), a non-inflammatory vascular disease that can cause narrowing of arteries in the carotid (neck) and renal (kidney) arteries, which can result in headache, strokes, and aneurysms.
Many patients with type 2 diabetes may be aspirin resistant. That means the standard aspirin dose may not protect them against blood clots that cause heart attacks and strokes among diabetics, a new clinical study finds. The results will be presented Sunday at The Endocrine Society's 94th Annual Meeting in Houston.
A new study has found that programs aimed at helping people prevent or manage diabetes are most successful if they are directed at the patient or the health care system. Programs aimed at physicians were only successful for patients with poorer diabetes control.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding a supplemental New Drug Application (sNDA) for XARELTO (rivaroxaban) for the reduction of the risk of secondary cardiovascular events in patients with acute coronary syndrome (ACS).
Depomed, Inc. today announced that it has acquired all rights to Zipsor (diclofenac potassium) Liquid Filled Capsules from Xanodyne Pharmaceuticals, Inc. Zipsor is a non-steroidal anti-inflammatory drug (NSAID) indicated for relief of mild to moderate acute pain in adults.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.